Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the European launch of MolecuLight i:X, the easy to use, handheld imaging device that instantly measures wound surface area and visualises the presence and distribution of potentially harmful bacteria in wounds.2,3
Currently wound assessments are made with the naked eye which can lack the accuracy required to most effectively guide clinical decision making.4Using fluorescence, MolecuLight i:X quickly, safely, and easily visualises potentially harmful bacteria1,2,3 in wounds which may otherwise lack signs or symptoms of infection. It enhances a clinician’s ability to choose the right therapy, at the right time for their patient1,2 and can help to guide wound sampling and debridement,1,5,6 monitor wound progression,2,3 improve patient engagement4,5 and simplify wound documentation.1
Clinical data from wound assessments demonstrates that incorporating the MolecuLight i:X into standard care facilitated more objective medical decision making and led to up to nine times faster wound healing1 and 54% more accurate swabbing.7
“The MolecuLight i:X enables healthcare professionals to see what they have never been able to see before“ said Paolo Di Vincenzo, Smith & Nephew’s Senior Vice President Global Marketing, Wound. “We are proud to partner with MolecuLight Inc. and bring this innovative technology to our customers. It strongly complements our range of advanced wound care products and we believe is set to start a revolution in wound care clinical practice.”
“For the first time clinicians can accurately sample a wound in situ to determine if bacteria are present as well as more effectively debride a wound under fluorescence visualisation. These are fundamental areas of everyday wound care that have remained suboptimal for too long, until now,” says Dr. Ralph DaCosta, Founder, Chief Scientific Officer and Director, MolecuLight Inc.
An estimated two million people are living with a chronic wound across Europe and an estimated 16% of all chronic wounds remain unresolved after a year or longer.9,10,11 Ensuring wounds are appropriately diagnosed and treated is a priority for healthcare providers across Europe, reducing cost and improving outcomes for patients.
“Not only has the MolecuLighti:X transformed my department’s clinical decision making in terms of targeting sampling and debridement and improving antimicrobial stewardship, but the benefit to patients has also been exciting to see,” says Rosemary Hill*, Canadian Wound Ostomy Continence Nurse Clinician, Lions Gate Hospital, Vancouver. “By being able to engage patients in their wound healing progress, and by showing them the real-time images, we can reduce anxiety, and provide reassurance regarding the diminishing burden of bacteria.”
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has more than 15,000 employees and a presence in more than 100 countries. Annual sales in 2016 were almost $4.7 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.
To learn more about what we do to help reduce wound infection, please visit www.closertozero.com
Access original Press Release here:
2. MolecuLight Inc. PN 1189 MolecuLight i:X User Manual. 2016.
3. MolecuLight Inc. Case Study 0051 Track Wound Size and Bacterial Presence with the MolecuLight i:X 2016.
4. Hoeflok J et al.. Pilot clinical evaluation of surgical site infections with a novel handheld fluorescence imaging device. Proceedings of the Annual Military Health System Research Symposium (MHSRS); 2014 Aug 18- 21; Fort Lauderdale, FL.
5. Raizman R. Point-of-care fluorescence imaging device guides care and patient education in obese patients with surgical site infections. Presented at: CAWC 2016. Proceedings of the Annual Canadian Association of Wound Care Conference (CAWC); 2016 Nov 3-6, Niagara Falls, ON.
6. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Proceedings of the Annual Wounds UK Conference; 2016 Nov 14-16; Harrogate, UK.
7. Ottolino-Perry K et al. Improved detection of wound bacteria using fluorescence image guided wound sampling in diabetic foot ulcers. Int Wound J. 2017 Feb 28. doi: 10.1111/iwj.12717.
8. Posnett J et al. J. Wound Care (April 2009), The Resource Impact of Wounds on Health-care Providers in Europe, vol.18 (4).
9. Lindholm C and Searle R. Wound management for the 21st century: combining effectiveness and efficiency. Int Wound J. 2016 Jul;13 Suppl 2:5-15.
10. Siddiqui AR and Bernstein JM. Chronic wound infection: facts and controversies. Clin Dermatol. 2010;28:519–26.
11. Vowden P. Hard-to-heal wounds made easy. Wounds International, Schofield Healthcare Media Ltd: Norwich, UK, 2011;2. URL: Wounds International
* Rosemary Hill is a paid consultant of Smith & Nephew or MolecuLight Inc.
The MolecuLight i:X is distributed by Smith & Nephew